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Abstract
Background: Both chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) are failing drugs in
much of sub-Saharan Africa. Previous findings suggest an association between resistance to CQ and
to SP in vivo, in vitro, and on the molecular level.
Methods: In 126 Ghanaian children with uncomplicated malaria, associations between mutations
conferring resistance in the Plasmodium falciparum dihydrofolate reductase (dhfr; SP) and chloroquine
resistance transporter (crt; CQ) genes, concentrations of residual antimalarial drugs, and gametocyte
carriage were examined.
Results: Mutant dhfr alleles and the CQ-resistance allele crt T76 were strongly associated with
each other. Isolates exhibiting the dhfr triple mutation seven times more likely also contained crt
T76 parasites as compared to isolates without the dhfr triple variant (P = 0.0001). Moreover, both,
isolates with the dhfr triple mutation (adjusted OR, 3.2 (95%CI, 1.0–10.4)) and with crt T76
(adjusted OR, 14.5 (1.4–150.8)) were associated with an increased likelihood of pre-treatment
gametocytaemia. However, crt T76 did not correlate with gametocytaemia following SP treatment
and no selection of crt T76 in SP treatment failure isolates was observed.
Conclusion: These results confirm an association between CQ and SP resistance markers in
isolates from northern Ghana. This could indicate accelerated development of resistance to SP if
CQ resistance is already present, or vice versa. Considering the enhanced transmission potential
as reflected by the increased proportion of isolates containing gametocytes when resistant
parasites are present, co-resistance can be expected to spread in this area. However, the
underlying mechanism leading to this constellation remains obscure.
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Background
Chloroquine (CQ) and sulfadoxine-pyrimethamine (SP)
are the most frequently used antimalarial drugs in sub-
Saharan Africa. With the spread and intensification of
drug resistance of Plasmodium falciparum more effective
combinatory drug regimes are now introduced in many
African countries [1]. However, CQ and SP are cheap and
widely available and will most likely be in use for some
more years, particularly in home treatment [2-4].
In several East African countries where SP was introduced
in response to intense CQ-resistance, the drug has gradu-
ally lost efficacy although the pace of this development is
subject to controversy [5,6]. Previously, the core muta-
tions linked with resistance to CQ and SP were found to
be associated with each other in isolates from southern
Ghana [7]. Although CQ and SP are structurally unrelated
and the mutations conferring resistance are located on
separate chromosomes [8-10], this finding suggests that
parasites resistant to CQ may acquire resistance to SP
more easily than sensitive ones, or vice versa. Studies in
murine models [11] and in vitro [12,13] support this
hypothesis. If this was true, the spread of CQ resistance
could pave the way for an accelerated development of SP
resistance, and thus, bear substantial importance to the
health systems of affected regions. In addition, transmis-
sion potential may be increased in both SP and CQ resist-
ant parasites [14,15].
Recently, mutations in the P. falciparum dihydrofolate
reductase (dhfr) gene in northern Ghana were observed not
only to be predictive for SP treatment failure but also to be
associated with increased pre-treatment gametocyte car-
riage [16]. Here, associations between dhfr alleles, the core
mutation in the P. falciparum chloroquine resistance trans-
porter gene (crt T76), residual antimalarials, and gameto-
cyte carriage in children with uncomplicated malaria were
re-examined.
Methods
P. falciparum isolates were collected from children with
uncomplicated malaria participating in a treatment trial
in Tamale, Northern Region, Ghana, at the end of the
rainy season 2002. The results of this trial and on the dhfr
and  dihydropteroate synthetase gene (dhps) patterns are
described elsewhere [16,17]. In the present report, data
from all 126 children with complete follow-up after SP
treatment for whom dhfr and dhps were genotyped are
analysed. The study protocol was approved by the Ethics
Committee, Ministry of Health, Northern Region, and by
the Health Research Unit, Ministry of Health, Accra, and
parents' informed consent was obtained.
Patients were children aged 6–59 months with uncompli-
cated P. falciparum monoinfection (≥ 2,000 ≤ 200,000/µL)
[18,19]. None had severe malnutrition, a febrile disease
other than malaria, "danger signs" [18], or severe malaria
[20]. Treatment consisted of a single dose of SP (25/1.25
mg/kg, Fansidar, Roche, Switzerland), and success was
monitored according to current guidelines [17,19].
Venous blood was collected into EDTA. Asexual parasites
and gametocytes were counted per ≥ 200 and 500 white
blood cells, respectively, on Giemsa-stained thick blood
films, and densities were calculated based on a putative
mean WBC count of 8,000/µL. Gametocyte counts one
week following treatment were available for 104 children.
Pre-treatment levels of CQ and pyrimethamine in blood
were measured by ELISA assays [21] with limits of detec-
tion of 10 ng/mL and 25 ng/mL, respectively.
P. falciparum dhfr, dhps, and crt alleles were assessed by
restriction fragment length polymorphisms (RFLP) of
amplicons generated by nested PCR assays applying hot
start procedures (HotStart Taq, Qiagen, Germany). Prim-
ers and conditions are described elsewhere [22,23] as are
restriction enzymes and RFLP conditions to characterize
the codons dhfr, 16, 51, 59, 108, 164; dhps, 436, 437, 540,
581, 613; and crt, 76. Laboratory strains were used as con-
trols for PCR and RFLP assays. Electrophoresis was per-
fomed on 3% GTG agarose (FMC Bioproducts, USA) gels.
Frequencies were compared by χ2-test or Fisher's exact
test, and continuous variables by Student's t-test, Mann-
Whitney U-test, or Kruskal-Wallis test as applicable. Logis-
tic regression models were used to adjust for potential
confounders of the presence of resistance mutations and
to identify risk factors for gametocytaemia.
Results
The median age of the 68 girls and 58 boys was 28.5
months (range, 6–59). Median axillary temperature and
geometric mean parasite density were 38.8°C (range,
37.5–41.0) and 36,358/µL (range, 2,068–175,333/µL),
respectively. Gametocytes were found in 19% (24/126) of
the children at a geometric mean density of 50/µL (16–
1,120/µL). CQ in blood was observed in 66% (83/126;
median, 32 ng/mL, range, 10–718) but pyrimethamine in
only two children (78 & 326 ng/mL).
The dhfr alleles Thr-108, Val-16 and Leu-164 were not
detected. Classifying mixed alleles as mutant, dhfr Ile-51
occurred in 56% (70/126), Arg-59 in 65% (82/126), and
Asn-108 in 72% (91/126). Triple dhfr mutations (Ile-51/
Arg-59/Asn-108) were seen in 47% (59/126), and quad-
ruple (triple dhfr + dhps Gly-437) and quintuple (triple
dhfr + dhps Gly-437/Glu-540) variants in 44% (55/126),
and 0.8% (1/126), respectively. Crt T76 occurred in 80%
(101/126) of the isolates.Malaria Journal 2005, 4:42 http://www.malariajournal.com/content/4/1/42
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The concomitant occurrence of dhfr, dhps, and crt alleles in
identical isolates was analyzed. All dhfr mutations were
linked with each other. Dhfr Ile-51 was associated with
Asn-108 (OR, 29.8; 95%CI, 8.0–161, P < 0.0001) and
Arg-59 (OR, 7.7; 95%CI, 3.3–19,5, P < 0.0001). All iso-
lates exhibiting dhfr Arg-59 additionally had Asn-108 (P <
0.0001). Notably, in isolates with dhfr variant parasites,
the CQ-resistance allele crt  T76 occurred significantly
more frequent than in the respective wildtype isolates
(Tab. 1). Separating isolates into such with e.g. dhfr codon
108 pure wildtype, wildtype & mutant, and pure mutant,
the prevalence of crt T76 was 67.5% (23/35), 82.4% (14/
17), and 86.5% (64/74), respectively (χ2
trend = 6.1; P =
0.01). Basically the same trend was seen for dhfr codons
51 (P = 0.002) and 59 (P = 0.002, data not shown). Vice
versa, in isolates with crt wildtype, with both crt wildtype
& T76, and crt T76 alone, the dhfr triple mutation was
detected in 16% (4/25), 53% (9/17), and 55% (46/84),
respectively.
The prevalence of crt  T76 increased with increasing
number of any dhfr mutations: it was 63% (20/32) in iso-
lates with pure dhfr wildtype, 74% (26/35) in isolates with
single or double mutations, and 93% (55/59) in isolates
exhibiting the dhfr  triple mutation (χ2
trend = 13.1; P  =
0.0003). Adjusting for CQ in blood, isolates with dhfr tri-
ple mutations revealed a seven-fold increased odds of
concomitantly exhibiting crt T76 (Tab. 1). Dhps alleles
neither correlated with dhfr alleles nor with crt T76 (data
not shown).
Dhfr, dhps, and crt alleles were examined with respect to
pre-treatment gametocytaemia. As reported elsewhere
[16], children were significantly more likely to harbour
gametocytes in the presence of dhfr 51, 59, or triple muta-
tions. This was also true for isolates exhibiting crt T76
(Tab. 2). Gametocytes were not observed in any (0/21)
isolate with wildtype alleles for both dhfr and crt, but in
16% (8/50) of isolates exhibiting either dhfr or crt muta-
tions, and in 29% (16/55) of isolates revealing both, dhfr
triple and crt T76 (χ2
trend = 8.7, P = 0.003). Adjusting for
additional factors influencing gametocytaemia, i.e. high
parasite density arbitrarily set as >50,000/µL, the presence
of CQ in blood, and axillary temperature, both the dhfr
triple mutation and crt  T76 were associated with an
increased likelihood of gametocytaemia (Tab. 2). Dhfr
alleles or crt T76 were not associated with gametocyte den-
sity (data not shown).
One week after treatment, gametocytes were observed in
63% (66/104) of the children. Gametocytaemia following
SP treatment was associated with pre-treatment dhfr muta-
tions, e.g. dhfr Asn-108, OR 3.1; 95%CI, 1.3–7.6. In chil-
dren harbouring crt T76 parasites, gametocytes were only
slightly more frequent (66% (54/82)) than in patients
with crt wildtype parasites (55% (12/22), P = 0.3).
Finally, selection of crt T76 in SP treatment failures was
examined. No selection was observed: In matched pairs of
isolates obtained from 35 children suffering SP treatment
failure, crt T76 was present in 86% (30/35) of pre-treat-
ment isolates and in 80% (28/35) of isolates obtained at
treatment failure.
Table 1: Associations between dhfr and crt mutations in 126 Ghanaian children with uncomplicated malaria
dhfr mutation Prevalence of crt T76 mutation (%) Odds ratio (95%CI) of crt T76 being present
Unadjusted P Adjusted for CQ in blood* P
51
absent 67.9 (38/56) 1 1
present 90.0 (63/70) 4.3 (1.5–12.5) 0.002 5.0 (1.8–13.8) 0.002
59
absent 63.6 (28/44) 1 1
present 89.0 (73/82) 4.6 (1.7–13.0) 0.0007 4.4 (1.7–11.4) 0.002
108
absent 65.7 (23/35) 1 1
present 85.7 (78/91) 3.1 (1.2–8.6) 0.01 3.2 (1.2–8.2) 0.02
triple
absent 68.7 (46/67) 1 1
present 93.2 (55/59) 6.3 (1.9–26.6) 0.0006 7.0 (2.2–22.5) 0.001
dhfr, dihydrofolate reductase gene, crt, chloroquine resistance transporter gene; 95%CI, 95% confidence interval; CQ, chloroquine; *, Potential 
confounders were tested for in logistic regression models including age, sex, parasite density, dhps alleles, and axillary temperature. Adjusted odds 
ratios include the presence of chloroquine in blood as the only factor found to be associated (univariate odds ratio, 3.2; 95%CI, 1.2–8.6; P = 0.01).Malaria Journal 2005, 4:42 http://www.malariajournal.com/content/4/1/42
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Discussion
In this study on P. falciparum isolates from northern
Ghana, two major findings are presented. First, SP and CQ
resistance markers are strongly associated with each other,
independent of residual antimalarials. Second, both are
associated with an increased prevalence of gametocytes.
This study has several limitations and particularly the
finding of an association between unrelated mutations
needs caution in interpretation. Because polyclonal infec-
tions predominate in the area [24], the detection of a
mutant allele in an isolate does not necessarily mean that
all clones carry the mutation. Thus, it cannot be stated
whether the linkage between the resistance markers is a
true one, i.e. on the chromosomal level, or reflects co-
occurrence in individual isolates. The limited number of
crt wildtypes also hampered proper testing of a linkage
disequilibrium. Although dhfr  mutations were signifi-
cantly more common in the presence of crt T76 this obser-
vation needs to be construed with caution since 80% of
the isolates in this study harboured the latter variant. Also,
it is impossible to comment whether the presence of crt
T76 favours the presence of dhfr mutations or vice versa
because this requires longitudinal observations. Likewise,
the lack of temporal information impairs a clear state-
ment on whether resistance mutations bring about
increased gametocytogenesis. Due to methodology the
resistance genotype of asexual parasites cannot be sepa-
rated from that of gametocytes.
Despite these difficulties in drawing firm conclusions, sev-
eral previous findings support the hypothesis of a linkage
disequilibrium between mutations associated with SP
resistance and CQ resistance. Early reports from the 1950s
and 1960s indicated that in areas or patients with estab-
lished pyrimethamine-resistance in Nigeria, Burkina Faso,
and Venezuela, CQ exhibited a reduced activity (reviewed
in [25]). In a murine malaria model, CQ resistance could
be induced in pyrimethamine-resistant parasites but not
in sensitive ones [11]. In isolates from Cameroon, the in
vitro activity of pyrimethamine was ten times lower in CQ
resistant than in sensitive P. falciparum [13]. Similar but
less pronounced differences have also been observed in
other studies [26,27]. In southern Ghana, we previously
observed that the dhfr core mutation Asn-108 was three
times more likely found in isolates exhibiting crt T76 than
in isolates comprising crt wildtype parasites [7]. The rea-
son for this apparent association between resistance to
CQ and pyrimethamine or SP is obscure since both drugs
have distinct modes of action and resistance to these is
determined by mutations on different chromosomes [8-
10]. One alluringly simple explanation could be that par-
asites in the study area have merely become resistant to
both drugs, possibly as a result of drug pressure. In this
regard, previous, simultaneous or sequential treatment
with CQ and SP could have selected for resistant parasites
which subsequently persisted for a longer period than the
drugs can be detected in blood. However, pyrimethamine
was seen in only two children which indicates that it is
rarely used in this community and which argues against
drug-induced selection for SP resistance. In addition, the
results are corrected for the presence of CQ in blood
which can be detected for approximately one month after
intake [28]. This does not exclude the possibility of
selected and persisting parasites but renders it rather
unlikely. Alternatively, the association between crt T76
Table 2: Associations with pre-treatment gametocytemia in 126 Ghanaian children with uncomplicated malaria
Factor Prevalence of gametocytemia (%) Odds ratio (95%CI) of gametocytemia
Unadjusted P Multivariate P
CQ in blood
None 27.9 (12/43) 1 1
Present 14.5 (12/83) 0.4 (0.2–1.2) 0.07 0.3 (0.1–1.0) 0.04
Ax. temperature n.a. 0.3 (0.1–0.6) 0.0008 0.2 (0.1–0.5) 0.0009
Parasite density
< 50,000/µL 26.3 (20/76) 1 1
≥ 50,000/µL 8.0 (4/50) 0.2 (0.1–0.8) 0.01 0.2 (0.1–0.8) 0.02
dhfr triple mutation
Absent 10.4 (7/67) 1 1
Present 28.8 (17/59) 3.5 (1.2–10.2) 0.009 3.2 (1.0–10.4) 0.049
crt 76 mutation
Absent 4.0 (1/25) 1 1
Present 22.8 (23/101) 7.1 (1.0–304) 0.04 14.5 (1.4–150.8) 0.02
Ax., axillary; n.a., not applicableMalaria Journal 2005, 4:42 http://www.malariajournal.com/content/4/1/42
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and dhfr mutations could reflect a rapid mutator pheno-
type with the ability of accelerated resistance to multiple
drugs. This hypothesis originates from in vitro studies
observing that parasites resistant to common antimalar-
ials acquire resistance to structurally unrelated drugs more
rapidly than susceptible strains. The genetic basis of this
phenomenon is unknown but suggested to involve an
increased frequency of mutations per se and consequently
a higher probability of modified proteins which could
also include drug targets [12]. In fact, selection for high-
grade pyrimethamine resistance in vitro has been shown to
enhance the degree of overall genomic polymorphism
[29]. In this regard, it is noteworthy that crt T76 was more
frequently observed with increasing number of dhfr muta-
tions, i.e. with increasing degree of SP resistance.
In the present study, the association between the resist-
ance markers meets with an increased presence of gameto-
cytes in isolates comprising mutant dhfr  or  crt  alleles.
Gametocytaemia seemed to reflect a rather long duration
of infection as can be deduced from its low prevalence in
the presence of factors suggestive for acute disease, i.e.
high body temperature and parasite density, and previous
CQ treatment (Tab. 2). Again, an increased frequency of
resistance mutations in gametocytaemic children could
result from previous drug-related selection as outlined
above. However, increased gametocytaemia preceding
treatment has also been observed in infections subse-
quently found to be CQ resistant [30-32]. Hallett et al.
[15] reported that in patients with crt T76 parasites, game-
tocyte density was highly increased one week following
CQ treatment. In addition, gametocytes from patients car-
rying crt T76 parasites produced 38 times higher oocyst
burdens in the mosquito as compared to crt wildtype par-
asites. In Tamale, both residual CQ levels and parasites
with the crt T76 mutation are abundant [33], and a clear
association of crt T76 and pre-treatment gametocyte prev-
alence is seen. Only one crt wildtype isolate contained
gametocytes impairing a sound analysis of the effect of crt
T76 on gametocyte density. However, increased gameto-
cyte production by crt T76 parasites [15] in the presence of
residual CQ could partially explain the present finding.
The synthesis of both, crt and dhfr mutations being asso-
ciated and increased gametocytaemia in their presence,
gives rise to a grim scenario: Given that CQ resistant par-
asites have an improved transmission potential [15] the
association with SP resistance would contribute to an
accelerating spread of resistance to both drugs, particu-
larly in areas where CQ resistance is frequent. In the
present study, neither selection of crt T76 in SP treatment
failure was observed nor a significantly elevated propor-
tion of post-treatment gametocytaemia among children
initially harbouring crt T76 parasites. Although this was
not expected and would reflect an extraordinary rapid
process, both observations may be influenced by the
small sample size.
Conclusion
The present data provide evidence supporting a hypothe-
sis on a connection between resistance to CQ and SP sug-
gesting that both, CQ and SP resistance favour
transmission. This needs to be verified by carefully
designed longitudinal studies in regions of differing levels
of drug resistance and endemicity. Per se, antimalarial
treatment must be effective, and more effective than CQ
and SP, not only to reduce treatment failures but also the
transmission of potential co-resistance. Eventually, as this
has been shown to counterbalance enhanced transmis-
sion of resistant parasites [15] the results strongly support
combinatory treatment including artemisinine-deriva-
tives.
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